Anti-tumor Effect of SLPI on Mammary But Not Colon Tumor Growth

AMIANO, NICOLÁS; COSTA, MARÍA J.; REITERI, R. MACARENA; PAYES, CRISTIAN; GUERRIERI, DIEGO; TATEOSIAN, NANCY; SANCHEZ, MERCEDES; MAFFIA, PAULO; DIAMENT, MIRIAM; KARAS, ROMINA; ORQUEDA, ANDRÉS; RIZZO, MIGUEL; ALANIS, LAURA; MAZZOLINI, GUILLERMO; KLEIN, SLOBODANKA; SALLENAVE, JEAN MICHELE; CHULUYAN, EDUARDO

JOURNAL OF CELLULAR PHYSIOLOGY

WILEY-LISS, DIV JOHN WILEY & SONS INC

Lugar: New York; Año: 2013 vol. 228 p. 469 - 475

0021-9541

Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor that was related to cancer development and metastasisdissemination on several types of tumors. However, it is not known the effect of SLPI on mammary and colon tumors. The aim of this studywas to examine the effect of SLPI on mammary and colon tumor growth. The effect of SLPI was tested on in vitro cell apoptosis and in vivotumor growth experiments. SLPI over-expressing human and murine mammary and colon tumor cells were generated by genetransfection. The administration of murine mammary tumor cells over-expressing high levels of SLPI did not develop tumors in mice.On the contrary, the administration of murine colon tumor cells over-expressing SLPI, developed faster tumors than control cells.Intratumoral, but not intraperitoneal administration of SLPI, delayed the growth of tumors and increased the survival of mammary but notcolon tumor bearing mice. In vitro culture of mammary tumor cell lines treated with SLPI, and SLPI producer clones were more prone toapoptosis than control cells, mainly under serum deprivation culture conditions. Herein we demonstrated that SLPI induces the apoptosisof mammary tumor cells in vitro and decreases the mammary but not colon tumor growth in vivo. Therefore, SLPI may be a new potentialtherapeutic tool for certain tumors, such as mammary tumors.